TABLE 1.
Susceptibility phenotypes evaluated using reference methods according CLSI, comparison with flow cytometry assay.
| BMD |
FASTinov versus BMD |
|||||||||
| Antimicrobial | n | MIC intervale μg/ml | S | I | R | mE | ME | VME | CA | |
| Gram negative bacilli | Ampicillin | 65 | 1–≥64 | 15 | – | 50 | 0 | 0 | 0 | 100% |
| Amoxicillin-clavulanic acid | 65 | 0.06/4–≥32/4 | 16 | 1 | 48 | 2 | 3 | 0 | 92.3% | |
| Piperacillin-tazobactam | 65 | ≤0.125/4–≥64/4 | 56 | 1 | 8 | 4 | 0 | 0 | 93.9% | |
| Cefpodoxime | 65 | 0.06–≥64 | 52 | 1 | 12 | 0 | 0 | 0 | 100% | |
| Imipenem | 65 | 0.25–≥64 | 60 | 3 | 2 | 3 | 1 | 0 | 93.9% | |
| Enrofloxacin | 65 | ≤0.06–≥32 | 46 | 2 | 17 | 2 | 1 | 0 | 95.4% | |
| Gentamicin | 65 | ≤0.125–≥32 | 56 | 2 | 7 | 3 | 1 | 0 | 93.9% | |
| Amikacin | 65 | 0.06–64 | 58 | 2 | 5 | 3 | 0 | 0 | 95.4% | |
| Overall | 520 | 359 | 12 | 149 | 17 | 6 | 0 | 95.6% | ||
| Staphylococcus spp. | Penicillin | 30 | ≤0.06–36 | 6 | – | 24 | 0 | 1 | 0 | 96.7% |
| Cefoxitin | 30 | 0.25–8 | 23 | – | 7 | 1 | 1 | 0 | 93.3% | |
| Enrofloxacin | 30 | ≤0.06–≥32 | 28 | – | 2 | 1 | 0 | 0 | 96.7% | |
| Vancomycin | 30 | 0.06–1 | 30 | – | 2 | 0 | 0 | 93.3% | ||
| Enterococcus spp. | Ampicillin | 20 | 1–8 | 16 | 2 | 2 | 0 | 0 | 0 | 100% |
| Vancomycin | 20 | 0.5–8 | 16 | 2 | 2 | 0 | 0 | 0 | 100% | |
| Overall | 180 | 135 | 6 | 39 | 4 | 2 | 0 | 96.7% | ||
S-susceptible; I-intermediate and Resistant. Categorical agreement (CA) and number of errors: mE-minor errors; ME- major errors and VME-very major errors.